The board said it has received her resignation and will immediately begin the search for a successor. Brophy O’Connor will remain in her role during her notice period to ensure an orderly transition.

With support from international recruitment specialists, the board will assess both internal and external candidates as it looks for a new CEO who can help drive the company’s strategy, innovation, and long-term growth, it states.

“On behalf of the board, I would like to thank Bronwyn for her commitment and important contributions during her three years as CEO. We have seen Bronwyn grow as a leader and are proud to have been part of her journey. As she now takes the next step in an exciting new role, we see it as a great opportunity for her and respect her decision,” said Jón Sigurdsson, chair of the board.

New CEO of the publicly listed Carl Zeiss Meditec

“It has been an honor and a privilege to lead Vitrolife Group. I will leave with mixed emotions and will miss our fantastic colleagues around the world, as well as the vision we share — to help people fulfill the dream of having a healthy child. Vitrolife Group is truly on its way to becoming the leading global partner in reproductive health. In the next phase of my career, I will join a well-established company in another area of the medtech industry at an exciting point in its history,” Brophy O’Connor says.

She has now been appointed new Executive Board Member of Carl Zeiss AG responsible for the Medical Technology segment and the new CEO of the publicly listed Carl Zeiss Meditec AG.